Potassium binders and continuation of renin-angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database) - PubMed
4 hours ago
- #RAASi persistence
- #Hyperkalemia management
- #Potassium binders
- Hyperkalemia often leads to discontinuation of RAASi (RASi and MRAs) in CKD and HF patients, despite their benefits.
- Real-world evidence on whether potassium binders enable RAASi continuation and improve outcomes was scarce; this study used Swedish data to investigate.
- Second-generation potassium binders were associated with higher RAASi persistence at 6 months compared to first-generation binders.
- Patients maintaining RASi therapy had lower observed rates of all-cause mortality and hospitalization, but no difference in 3P-MACE.
- Findings suggest potassium binders may help sustain RAASi use in non-dialysis CKD and/or HF patients, potentially improving clinical outcomes.